The National Cancer Institute (NCI) announced an opportunity for current NCI-funded Principal Investigators whose postdoctoral fellows have temporarily lost stipend support from a non-profit funder because of the COVID-19 pandemic to apply for a funding supplement to cover the fellow’s salary and applicable facilities and administrative costs for the time and effort devoted to the NCI-funded grant.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
In testimony submitted to Congress about the federal budget for FY 2021, ASCO thanked lawmakers for increasing funding for cancer research in FY2020 and urged them to increase funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the Centers for Disease Control and Protection (CDC) in the year ahead.
The Association for Clinical Oncology (ASCO) is calling on Members of Congress to continue their support for federally funded research by providing $44.7 billion for the National Institutes of Health (NIH), including $6.9 billion for the National Cancer Institute (NCI) in Fiscal Year (FY) 2021. The $3 billion funding increase for NIH will help the agency continue to regain some of the ground it lost after years of effectively flat budgets so the U.S. biomedical research enterprise can continue its important work in support of new advances and cures for patients.
The meetings focused on drug pricing, access to clinical trials, Medicaid expansion and block grants, accelerated drug approval pathways, and other issues affecting people with cancer and their oncology care teams.
President Trump recently signed into law a bill that funds the federal government for Fiscal Year (FY) 2020 and raises the purchasing age of tobacco products to 21.